Ulimorelin
Ulimorelin (TZP-101) is a ghrelin receptor (GRLN) agonist with an EC50 of 29 nM and a Ki of 16 nM. Ulimorelin is a prokinetic agent and causes vasorelaxation through competitive antagonist action at α1-adrenoceptors. Ulimorelin stimulates intestinal motility and is used for malnutrition[1][2][3].
Product Specifications
CAS Number
842131-33-3
Product Name Alternative
TZP-101
UNSPSC
12352005
Target
Adrenergic Receptor; GHSR
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/ulimorelin.html
Purity
96.10
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(N(C)[C@H](C)C(N[C@@H]1CC2=CC=C(F)C=C2)=O)[C@H](C3CC3)NC[C@@H](C)OC4=CC=CC=C4CCCNC1=O
Molecular Formula
C30H39FN4O4
Molecular Weight
538.65
References & Citations
[1]Pustovit RV, et al. The mechanism of enhanced defecation caused by the ghrelin receptor agonist, ulimorelin. Neurogastroenterol Motil. 2014 Feb;26 (2) :264-71.|[2]Broad J, et al. Analysis of the ghrelin receptor-independent vascular actions of ulimorelin. Eur J Pharmacol. 2015 Apr 5;752:34-9. |[3]Hoveyda HR, et al. Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I) : Development of ulimorelin (TZP-101) from hit to clinic. J Med Chem. 2011 Dec 22;54 (24) :8305-20.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
α adrenergic receptor
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K3713906 1.0 µg DNA
Elavl2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1)
Sign In for Pricing
View Details 
MBS7011055-01 0.02 mg
Recombinant Papio hamadryas C-C chemokine receptor type 5 (CCR5)
Sign In for Pricing
View Details MBS7011055-02 0.1 mg
Recombinant Papio hamadryas C-C chemokine receptor type 5 (CCR5)
Sign In for Pricing
View Details